US7301021B2
(en)
|
1997-07-02 |
2007-11-27 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
US7517880B2
(en)
*
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
US7329670B1
(en)
*
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
ES2221426T3
(es)
|
1998-08-20 |
2004-12-16 |
Smithkline Beecham Corporation |
Nuevos compuestos de triazol sustituidos.
|
US6525069B1
(en)
|
1998-12-18 |
2003-02-25 |
Bristol-Myers Squibb Pharma Co. |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
WO2000042012A1
(en)
*
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
US7351834B1
(en)
*
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
EP2298311B1
(en)
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
EP1157026A1
(en)
|
1999-02-22 |
2001-11-28 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Polycyclo heterocyclic derivatives as antiinflammatory agents
|
EE04799B1
(et)
|
1999-03-12 |
2007-04-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
|
ES2251360T3
(es)
|
1999-03-12 |
2006-05-01 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Compuestos heterociclicos aromaticos en calidad de agentes antiinflamatorios.
|
ES2253233T3
(es)
|
1999-07-09 |
2006-06-01 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
|
US6759410B1
(en)
*
|
1999-11-23 |
2004-07-06 |
Smithline Beecham Corporation |
3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
WO2001098270A2
(en)
*
|
2000-06-21 |
2001-12-27 |
Bristol-Myers Squibb Pharma Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
WO2002007772A2
(en)
*
|
2000-07-24 |
2002-01-31 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Improved oral dosage formulations
|
ES2318649T3
(es)
|
2000-10-20 |
2009-05-01 |
EISAI R&D MANAGEMENT CO., LTD. |
Procedimiento de preparacion de derivados de 4-fenoxi quinolinas.
|
CA2435446A1
(en)
*
|
2001-02-15 |
2002-08-29 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents
|
CA2445003A1
(en)
|
2001-05-16 |
2002-11-21 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Diarylurea derivatives useful as anti-inflammatory agents
|
JP2004531571A
(ja)
|
2001-05-25 |
2004-10-14 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
|
AU2002310156A1
(en)
|
2001-06-05 |
2002-12-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-disubstituted benzo-fused cycloalkyl urea compounds
|
EP1709965A3
(en)
|
2001-07-11 |
2006-12-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediate diseases
|
US6916814B2
(en)
|
2001-07-11 |
2005-07-12 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediated diseases
|
US6808721B2
(en)
*
|
2001-07-11 |
2004-10-26 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods for coating pharmaceutical core tablets
|
CA2454913A1
(en)
*
|
2001-08-20 |
2003-02-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin
|
AU2002333464A1
(en)
|
2001-08-31 |
2003-03-18 |
Bayer Chemicals Ag |
Method for producing 4-amino-1-naphthol ethers
|
JP2005503400A
(ja)
*
|
2001-09-13 |
2005-02-03 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン媒介病の治療方法
|
JP2005506350A
(ja)
|
2001-10-18 |
2005-03-03 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン阻害薬としての1,4−二置換ベンゾ−縮合尿素化合物
|
US20030118575A1
(en)
*
|
2001-12-11 |
2003-06-26 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Method for administering BIRB 796 BS
|
AU2003210969A1
(en)
*
|
2002-02-11 |
2003-09-04 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenesis inhibiting activity
|
MXPA04007832A
(es)
|
2002-02-11 |
2005-09-08 |
Bayer Pharmaceuticals Corp |
Aril-ureas con actividad inhibitoria de angiogenesis.
|
US20030216396A1
(en)
|
2002-02-11 |
2003-11-20 |
Bayer Corporation |
Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
|
WO2003068746A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Aryl ureas as kinase inhibitors
|
WO2003072569A1
(en)
*
|
2002-02-25 |
2003-09-04 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
|
US20030225089A1
(en)
*
|
2002-04-10 |
2003-12-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
|
US20030236287A1
(en)
*
|
2002-05-03 |
2003-12-25 |
Piotrowski David W. |
Positive allosteric modulators of the nicotinic acetylcholine receptor
|
US20040044020A1
(en)
*
|
2002-07-09 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors
|
EP1534282B1
(en)
|
2002-07-09 |
2006-12-27 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
|
JP2006504667A
(ja)
*
|
2002-08-08 |
2006-02-09 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
炎症過程に関与するサイトカインの抑制剤としてのフッ素化フェニル−ナフタレニル−尿素化合物
|
US7232828B2
(en)
*
|
2002-08-10 |
2007-06-19 |
Bethesda Pharmaceuticals, Inc. |
PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
|
US20040110755A1
(en)
*
|
2002-08-13 |
2004-06-10 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
|
EP1545514A1
(en)
*
|
2002-08-14 |
2005-06-29 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
|
ATE329909T1
(de)
*
|
2002-11-27 |
2006-07-15 |
Boehringer Ingelheim Pharma |
1,2,3-triazolamid-derivate als cytokininhibitoren
|
US20040138216A1
(en)
*
|
2002-12-23 |
2004-07-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Process for the preparation of an essentially pure polymorph of an n-pyrazolyl-n'-naphthyl-urea
|
US7279576B2
(en)
|
2002-12-31 |
2007-10-09 |
Deciphera Pharmaceuticals, Llc |
Anti-cancer medicaments
|
US7144911B2
(en)
*
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
US7202257B2
(en)
|
2003-12-24 |
2007-04-10 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
US20080045706A1
(en)
*
|
2002-12-31 |
2008-02-21 |
Flynn Daniel L |
Anti-inflammatory medicaments
|
DE202004021876U1
(de)
*
|
2003-02-21 |
2012-01-30 |
Resmed Limited |
Nasale Anordnung
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
JP4594925B2
(ja)
*
|
2003-02-28 |
2010-12-08 |
ニッポネックス インコーポレイテッド |
増殖亢進性、血管新生性及び炎症性疾患の治療に有用な2−オキソ−1,3,5−パーヒドロトリアザピン誘導体
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
GB0320244D0
(en)
*
|
2003-05-06 |
2003-10-01 |
Aventis Pharma Inc |
Pyrazoles as inhibitors of tumour necrosis factor
|
WO2005016241A2
(en)
|
2003-05-16 |
2005-02-24 |
Intermune, Inc. |
Synthetic chemokine receptor ligands and methods of use thereof
|
JPWO2004101529A1
(ja)
*
|
2003-05-19 |
2006-07-13 |
小野薬品工業株式会社 |
含窒素複素環化合物およびその医薬用途
|
CA2526617C
(en)
|
2003-05-20 |
2015-04-28 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas with kinase inhibiting activity
|
US7405210B2
(en)
|
2003-05-21 |
2008-07-29 |
Osi Pharmaceuticals, Inc. |
Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
|
WO2004113352A1
(en)
*
|
2003-06-19 |
2004-12-29 |
Amedis Pharmaceuticals Ltd. |
Silylated heterocyclylurea derivatives as cytokine-inhibitors
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
UA84156C2
(ru)
|
2003-07-23 |
2008-09-25 |
Байер Фармасьютикалс Корпорейшн |
Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
|
BRPI0413757A
(pt)
*
|
2003-08-22 |
2006-10-31 |
Boehringer Ingelheim Pharma |
métodos para o tratamento de copd e da hipertensão pulmonar
|
JP4895811B2
(ja)
|
2003-09-11 |
2012-03-14 |
ケミア,インコーポレイテッド |
サイトカイン阻害剤
|
CN101337930B
(zh)
|
2003-11-11 |
2010-09-08 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
US7750160B2
(en)
|
2003-11-13 |
2010-07-06 |
Ambit Biosciences Corporation |
Isoxazolyl urea derivatives as kinase modulators
|
JP2007514791A
(ja)
*
|
2003-12-18 |
2007-06-07 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
P38mapキナーゼインヒビターであるbirb796の多形
|
US20070191336A1
(en)
*
|
2003-12-24 |
2007-08-16 |
Flynn Daniel L |
Anti-inflammatory medicaments
|
DE602005023965D1
(de)
|
2004-03-08 |
2010-11-18 |
Prosidion Ltd |
Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
|
EP1751139B1
(en)
|
2004-04-30 |
2011-07-27 |
Bayer HealthCare LLC |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
EP1609789A1
(en)
*
|
2004-06-23 |
2005-12-28 |
Eli Lilly And Company |
Ureido-pyrazole derivatives and their use as kinase inhibitors
|
WO2006009741A1
(en)
*
|
2004-06-23 |
2006-01-26 |
Eli Lilly And Company |
Kinase inhibitors
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
AU2005273612B2
(en)
|
2004-08-12 |
2010-10-14 |
Pfizer Inc. |
Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
|
US8969379B2
(en)
|
2004-09-17 |
2015-03-03 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
|
DE102004055633A1
(de)
*
|
2004-11-12 |
2006-05-18 |
Schering Ag |
5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
|
CN101098687A
(zh)
*
|
2004-11-17 |
2008-01-02 |
安吉奥根制药控股有限公司 |
调节b细胞功能的方法
|
US20080009519A1
(en)
*
|
2004-11-17 |
2008-01-10 |
Lawrence Steinman |
Method of modulating t cell functioning
|
ES2324173T3
(es)
|
2004-12-02 |
2009-07-31 |
Prosidion Limited |
Amidas del acido pirrolopiridin-2-carboxilico.
|
US7612200B2
(en)
|
2004-12-07 |
2009-11-03 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
WO2006062982A2
(en)
|
2004-12-07 |
2006-06-15 |
Locus Pharmaceuticals, Inc. |
Urea inhibitors of map kinases
|
CA2592116A1
(en)
*
|
2004-12-23 |
2006-08-03 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
JP5197016B2
(ja)
|
2004-12-23 |
2013-05-15 |
デシファラ ファーマスーティカルズ, エルエルシー |
酵素モジュレータ及び治療
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
RU2416610C2
(ru)
|
2004-12-30 |
2011-04-20 |
Астекс Терапьютикс Лимитед |
Фармацевтические соединения
|
WO2006124283A1
(en)
*
|
2005-05-12 |
2006-11-23 |
Boehringer Ingelheim International, Gmbh |
Bis-amination of aryl halides
|
WO2007015578A1
(ja)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を検定する方法
|
WO2007044490A2
(en)
*
|
2005-10-06 |
2007-04-19 |
Boehringer Ingelheim International Gmbh |
Process for making heteroaryl amine intermediate compounds
|
PE20070640A1
(es)
*
|
2005-10-28 |
2007-08-10 |
Lilly Co Eli |
Compuestos derivados de pirazol-isoquinolina urea como inhibidores de la cinasa p38
|
US8399666B2
(en)
|
2005-11-04 |
2013-03-19 |
Panmira Pharmaceuticals, Llc |
5-lipoxygenase-activating protein (FLAP) inhibitors
|
GB2431927B
(en)
|
2005-11-04 |
2010-03-17 |
Amira Pharmaceuticals Inc |
5-Lipoxygenase-activating protein (FLAP) inhibitors
|
US7977359B2
(en)
|
2005-11-04 |
2011-07-12 |
Amira Pharmaceuticals, Inc. |
5-lipdxygenase-activating protein (FLAP) inhibitors
|
JP2009518298A
(ja)
*
|
2005-12-01 |
2009-05-07 |
バイエル ヘルスケア リミティド ライアビリティ カンパニー |
癌治療に有用な尿素化合物
|
US8399442B2
(en)
|
2005-12-30 |
2013-03-19 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
US20070185098A1
(en)
*
|
2006-01-04 |
2007-08-09 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
JP5131990B2
(ja)
|
2006-01-31 |
2013-01-30 |
アレイ バイオファーマ、インコーポレイテッド |
キナーゼ阻害剤およびその使用方法
|
EP1987022A1
(en)
*
|
2006-02-10 |
2008-11-05 |
Pfizer Products Inc. |
Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives
|
KR20090018104A
(ko)
|
2006-05-08 |
2009-02-19 |
어리어드 파마슈티칼스, 인코포레이티드 |
아세틸렌계 헤테로아릴 화합물
|
BRPI0710331A2
(pt)
|
2006-05-08 |
2012-03-20 |
Ariad Pharmaceuticals, Inc |
Compostos heteroarila monocíclicos para tratamento de câncer e composição
|
CA2652442C
(en)
|
2006-05-18 |
2014-12-09 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
EP2049119A2
(en)
|
2006-06-29 |
2009-04-22 |
Astex Therapeutics Limited |
Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea
|
KR101472600B1
(ko)
|
2006-08-28 |
2014-12-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암에 대한 항종양제
|
US8188113B2
(en)
|
2006-09-14 |
2012-05-29 |
Deciphera Pharmaceuticals, Inc. |
Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
US7790756B2
(en)
|
2006-10-11 |
2010-09-07 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
|
US7737149B2
(en)
*
|
2006-12-21 |
2010-06-15 |
Astrazeneca Ab |
N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
|
CA2676796C
(en)
|
2007-01-29 |
2016-02-23 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
WO2008125014A1
(fr)
*
|
2007-04-13 |
2008-10-23 |
Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. |
Composés d'urée, leurs procédés de préparation et leurs utilisations pharmaceutiques
|
EP2146717A4
(en)
*
|
2007-04-20 |
2010-08-11 |
Deciphera Pharmaceuticals Llc |
KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYOLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES
|
US20110189167A1
(en)
*
|
2007-04-20 |
2011-08-04 |
Flynn Daniel L |
Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
US7868001B2
(en)
*
|
2007-11-02 |
2011-01-11 |
Hutchison Medipharma Enterprises Limited |
Cytokine inhibitors
|
WO2009060945A1
(ja)
|
2007-11-09 |
2009-05-14 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質と抗腫瘍性白金錯体との併用
|
EP2111861A1
(en)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type IV inhibitors
|
CN102137858B
(zh)
|
2008-05-23 |
2014-07-23 |
潘米拉制药有限责任公司 |
5-脂氧合酶-活化蛋白抑制剂
|
ES2537529T3
(es)
|
2008-06-05 |
2015-06-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Novedosos moduladores de la señalización de proteínas cinasas
|
MX2011003553A
(es)
|
2008-10-02 |
2011-05-25 |
Respivert Ltd |
Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38.
|
GB0818033D0
(en)
*
|
2008-10-02 |
2008-11-05 |
Respivert Ltd |
Novel compound
|
BRPI0920765A2
(pt)
*
|
2008-10-29 |
2015-08-18 |
Deciphera Pharmaceuticals Llc |
Amidas de cilopropano e análogos que exibem atividades anticâncer e antiproliferativas
|
FR2937973B1
(fr)
*
|
2008-11-04 |
2010-11-05 |
Galderma Res & Dev |
Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
|
US8846664B2
(en)
|
2008-11-12 |
2014-09-30 |
Ariad Pharmaceuticals, Inc. |
Pyrazinopyrazines and derivatives as kinase inhibitors
|
MX2011006219A
(es)
|
2008-12-11 |
2011-06-28 |
Respivert Ltd |
Inhibidores de la proteina cinasa activada por el mitogeno p38.
|
NZ595372A
(en)
|
2009-03-27 |
2013-11-29 |
Vetdc Inc |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
ES2634470T3
(es)
|
2009-09-30 |
2017-09-27 |
Toray Industries, Inc. |
Derivado de 2,3-dihidro-1H-inden-2-ilurea y aplicación farmacéutica del mismo
|
GB0921731D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Theraputic uses
|
GB0921730D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Method of treatment
|
GB201005589D0
(en)
|
2010-04-01 |
2010-05-19 |
Respivert Ltd |
Novel compounds
|
FR2993780B1
(fr)
*
|
2012-07-26 |
2015-02-13 |
Assist Publ Hopitaux De Paris |
Methode de traitement de la sclerose en plaque
|
EP2556068B1
(en)
|
2010-04-08 |
2019-01-23 |
Respivert Limited |
P38 map kinase inhibitors
|
WO2011124923A2
(en)
|
2010-04-08 |
2011-10-13 |
Respivert Limited |
Novel compounds
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
GB201009731D0
(en)
*
|
2010-06-10 |
2010-07-21 |
Pulmagen Therapeutics Inflamma |
Kinase inhibitors
|
WO2011158044A2
(en)
|
2010-06-17 |
2011-12-22 |
Respivert Limited |
Respiratory formulations and compounds for use therein
|
EP2586443B1
(en)
|
2010-06-25 |
2016-03-16 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
US9090592B2
(en)
*
|
2010-12-30 |
2015-07-28 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
CA2828946C
(en)
|
2011-04-18 |
2016-06-21 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
JP5933902B2
(ja)
|
2011-05-13 |
2016-06-15 |
アレイ バイオファーマ、インコーポレイテッド |
Trkaキナーゼ阻害剤としてのピロリジニル尿素およびピロリジニルチオ尿素化合物
|
ES2705950T3
(es)
|
2011-06-03 |
2019-03-27 |
Eisai R&D Man Co Ltd |
Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
|
PL2763984T3
(pl)
|
2011-10-03 |
2016-10-31 |
|
1-pirazolilo-3-(4-((2-anilinopirymidyno-4-ilo)oksy)naftaleno-1-ilo)moczniki jako inhibitory kinazy p38 MAP
|
EP2578582A1
(en)
|
2011-10-03 |
2013-04-10 |
Respivert Limited |
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
|
ES2596215T3
(es)
|
2011-10-24 |
2017-01-05 |
Asana Biosciences, Llc |
Ciclohexilaminas
|
CN103987708B
(zh)
*
|
2011-12-09 |
2016-06-22 |
奇斯药制品公司 |
4-羟基-1,2,3,4-四氢萘-1-基脲的衍生物及其在呼吸道疾病治疗中的用途
|
ES2897740T3
(es)
|
2011-12-28 |
2022-03-02 |
Kyoto Prefectural Public Univ Corp |
Normalización del cultivo de células endoteliales de la córnea
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
GB201214750D0
(en)
|
2012-08-17 |
2012-10-03 |
Respivert Ltd |
Compounds
|
WO2014033446A1
(en)
|
2012-08-29 |
2014-03-06 |
Respivert Limited |
Kinase inhibitors
|
WO2014033449A1
(en)
|
2012-08-29 |
2014-03-06 |
Respivert Limited |
Kinase inhibitors
|
GB201215357D0
(en)
|
2012-08-29 |
2012-10-10 |
Respivert Ltd |
Compounds
|
WO2014033447A2
(en)
|
2012-08-29 |
2014-03-06 |
Respivert Limited |
Kinase inhibitors
|
US9969694B2
(en)
|
2012-11-13 |
2018-05-15 |
Array Biopharma Inc. |
N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
WO2014078328A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078378A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9822118B2
(en)
|
2012-11-13 |
2017-11-21 |
Array Biopharma Inc. |
Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
WO2014078417A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9981959B2
(en)
|
2012-11-13 |
2018-05-29 |
Array Biopharma Inc. |
Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
WO2014078325A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
UA117573C2
(uk)
|
2012-11-13 |
2018-08-27 |
Ерей Біофарма Інк. |
Біциклічні сполуки сечовини, тіосечовини, гуанідину й ціаногуанідину, придатні для лікування болю
|
WO2014078372A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
CN107857755B
(zh)
|
2012-11-13 |
2020-10-27 |
阵列生物制药公司 |
作为trka激酶抑制剂的n-吡咯烷基、n′-吡唑基-脲、硫脲、胍和氰基胍化合物
|
EP2925742B1
(en)
|
2012-11-16 |
2016-10-26 |
Respivert Limited |
Kinase inhibitors
|
CN104755463A
(zh)
|
2012-12-21 |
2015-07-01 |
卫材R&D管理有限公司 |
非晶态形式的喹啉衍生物及其生产方法
|
WO2014140582A1
(en)
|
2013-03-14 |
2014-09-18 |
Respivert Limited |
Kinase inhibitors
|
DK2981535T3
(da)
|
2013-04-02 |
2021-03-01 |
Oxular Acquisitions Ltd |
Urinstofderivater, der er anvendelige som kinaseinhibitorer
|
WO2014162121A1
(en)
|
2013-04-02 |
2014-10-09 |
Topivert Pharma Limited |
Kinase inhibitors based upon n-alkyl pyrazoles
|
MX368099B
(es)
|
2013-05-14 |
2019-09-19 |
Eisai R&D Man Co Ltd |
Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
|
EP3004087B1
(en)
*
|
2013-06-06 |
2017-08-09 |
CHIESI FARMACEUTICI S.p.A. |
Derivatives of [1,2,4]triazolo[4,3-a]pyridine as p38-map kinase inhibitors
|
WO2015008206A1
(en)
|
2013-07-14 |
2015-01-22 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
|
EP3069732B1
(en)
|
2013-11-14 |
2023-07-12 |
The Doshisha |
Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
|
AU2014369449B2
(en)
|
2013-12-20 |
2018-07-05 |
Oxular Acquisitions Limited |
Urea derivatives useful as kinase inhibitors
|
DK3105222T3
(en)
*
|
2014-02-14 |
2018-07-23 |
Respivert Ltd |
AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY COMPOUNDS
|
RS59286B1
(sr)
|
2014-05-15 |
2019-10-31 |
Array Biopharma Inc |
1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea kao inhibitor trka kinaze
|
BR112016026556A8
(pt)
|
2014-05-16 |
2021-07-06 |
Atriva Therapeutics Gmbh |
inibidores de mek, de p38 e/ou de nfkb, seus usos, composição, sistema de teste in vitro, seu uso, e método para detecção de moléculas eficazes na profilaxia e/ou tratamento de uma co-infecção
|
JO3783B1
(ar)
|
2014-08-28 |
2021-01-31 |
Eisai R&D Man Co Ltd |
مشتق كوينولين عالي النقاء وطريقة لإنتاجه
|
SG11201701174VA
(en)
|
2014-08-29 |
2017-03-30 |
Torrent Pharmaceuticals Ltd |
P38 map kinase inhibiting indanyl urea compounds
|
MA40774A
(fr)
|
2014-10-01 |
2017-08-08 |
Respivert Ltd |
Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
|
CN112494653A
(zh)
|
2015-02-05 |
2021-03-16 |
特尔诺沃有限公司 |
用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
|
DK3263106T3
(da)
|
2015-02-25 |
2024-01-08 |
Eisai R&D Man Co Ltd |
Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
CN107801379B
(zh)
|
2015-06-16 |
2021-05-25 |
卫材R&D管理有限公司 |
抗癌剂
|
US20190060286A1
(en)
|
2016-02-29 |
2019-02-28 |
University Of Florida Research Foundation, Incorpo |
Chemotherapeutic Methods
|
JP6995774B2
(ja)
|
2016-04-06 |
2022-02-21 |
オクラー アクイジションズ リミテッド |
キナーゼ阻害剤
|
EP3582781A4
(en)
|
2017-02-15 |
2020-12-09 |
The University of Melbourne |
TREATMENT PROCEDURES
|
JP7148500B2
(ja)
*
|
2017-04-27 |
2022-10-05 |
持田製薬株式会社 |
新規テトラヒドロナフチルウレア誘導体
|
LT3691620T
(lt)
|
2017-10-05 |
2022-09-26 |
Fulcrum Therapeutics, Inc. |
P38 kinazės inhibitoriai, sumažinantys dux4 ir pasrovinių genų raišką, skirti fshd gydymui
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
CN111548313A
(zh)
*
|
2019-02-11 |
2020-08-18 |
绍兴从零医药科技有限公司 |
预防和治疗慢性疼痛药物的胍类化合物
|
ES2789898B2
(es)
|
2019-04-25 |
2021-10-14 |
Fund Profesor Novoa Santos |
Composicion para el tratamiento de los efectos secundarios de la radioterapia y/o quimioterapia
|
TW202112368A
(zh)
|
2019-06-13 |
2021-04-01 |
荷蘭商法西歐知識產權股份有限公司 |
用於治療有關dux4表現之疾病的抑制劑組合
|
MX2022001863A
(es)
|
2019-08-12 |
2022-05-30 |
Deciphera Pharmaceuticals Llc |
Metodos para tratar los tumores del estroma gastrointestinal.
|
TW202122082A
(zh)
|
2019-08-12 |
2021-06-16 |
美商迪賽孚爾製藥有限公司 |
治療胃腸道基質瘤方法
|
IL293864A
(en)
|
2019-12-30 |
2022-08-01 |
Deciphera Pharmaceuticals Llc |
Preparations of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3- phenylurea
|
LT4084778T
(lt)
|
2019-12-30 |
2024-01-25 |
Deciphera Pharmaceuticals, Llc |
Amorfinės kinazės inhibitoriaus vaistinės formos ir jų panaudojimo būdai
|
CN112961120B
(zh)
*
|
2021-02-06 |
2022-02-08 |
河南省锐达医药科技有限公司 |
一种萘基脲类化合物、其制备方法及应用
|
WO2023280911A1
(en)
|
2021-07-06 |
2023-01-12 |
Westfälische Wilhelms-Universität Münster |
P38-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm
|
CN114702439B
(zh)
*
|
2021-12-13 |
2023-11-10 |
河南省锐达医药科技有限公司 |
一类萘基脲-哌嗪类化合物及其制备方法和应用
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|